Statement of deviation(s) or variation(s) under Reg. 32

Date: October 29, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Submission of statement of Deviation or Variation in utilisation of funds of public issue for quarter ended on September 30, 2026 Dear Sir/Ma’am, Pursuant to Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD- 2/CIR/P/2024/185 dated December 31, 2024 and SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 , please find enclosed herewith the statement of deviation(s) or variation(s) for the quarter ended September 30, 2026 in respect of utilization of proceeds of the Initial Public Offer of the Company. We hereby confirm that there has been no deviation or variation in the utilisation of the proceeds of the IPO during the aforesaid period from the objects stated in the Prospectus dated December 24, 2024, as subsequently modified pursuant to the special resolution passed through postal ballot on August 03, 2026. The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on October 29, 2026. This intimation will also be made available on the website of the Company i.e. www.senorespharma.com. You are requested to take the same on record. Thanking you. For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary & Compliance Officer Membership Number: A34516 Enclosure: As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 STATEMENT OF DEVIATION(S) / VARIATION(S) IN UTILISATION OF FUNDS RAISED THROUGH IPO, FOR THE QUARTER ENDED SEPTEMBER 30, 2026 Name of listed entity Senores Pharmaceuticals Limited Mode of Fund Raising Initial Public offer Date of Raising Funds December 26, 2024 Amount Raised Rs. 500 Crores Report filed for Quarter ended September 30, 2026 Monitoring Agency Applicable Monitoring Agency Name, if applicable CARE Ratings Limited Is there a Deviation / Variation in use of No funds raised If yes, whether the same is pursuant to Not Applicable change in terms of a contract or objects, which was approved by the shareholders If Yes, Date of shareholder Approval Not Applicable Explanation for the Deviation / Variation Not Applicable Comments of the Audit Committee after No comments review Comments of the auditors, if any No comments (₹ in Crores) Objects for which funds have been raised and where there has been a deviation, in the following table Original Modified Original Modified Funds Amount of Remarks, if Object Object, if any Allocation Allocation, Utilized Deviation/ any if any Variation for the quarter according to applicable object Investment in Not 107.00 41.98 6.98 Not The cost of one of our Applicable Applicable the object Subsidiaries, has been Havix, to fund revised as capital per the expenditure shareholder requirements approval for setting up a dated manufacturing August 03, facility for the 2026 production of sterile injections in Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 our Atlanta Facility Re- 73.48 73.10 73.10 Not The payment/pre- Applicable unutilized payment, in full amount of or in part, of Rs. 0.38 certain crore has borrowings been availed by our transferred Company to objective-6 as resolved in the Board Meeting dated July 23, 2025 Investment in Not 20.22 20.20 20.20 Not The our Subsidiary, Applicable Applicable unutilized namely, Havix, amount of for re- Rs. 0.02 payment/pre- crore has payment in full been or in part, of transferred certain to borrowings objective-6 availed by such as resolved Subsidiaries in the Board Meeting dated July 23, 2025 Funding the Not 43.26 - 43.26 Not working capital Applicable Applicable requirements of our Company Investment in Not 59.48 Not 59.48 Not - our Applicable Applicable Applicable Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements Funding Not 154.37 161.91 161.91 Not Amount of inorganic Applicable Applicable Rs. 7.54 growth through crore has acquisition and been other strategic transferred initiatives and from general Objective 2, corporate 3 and 7. purposes Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Offer expenses Not 42.19 35.04 34.99 Not The Applicable Applicable unutilized amount of Rs. 6.31 crore under objective-7 has been transferred to objective- 6 as resolved in the Board Meeting dated March 28, 2026 and Rs. 0.84 crore as resolved in Board Meeting dated May 14, 2026. - Investment in - 15.40 10.08 Not New subsidiary Applicable objective SPI to fund added as per the the acquisition of shareholder ANDAs. approval dated August 03, 2026. - Investment in - 25.00 1.69 Not New one of the Applicable objective subsidiaries, added as Apnar, to fund per the the capital shareholder expenditure approval requirements dated for expansion August 03, of its existing 2026 manufacturing facility in Vadodara. - Investment in - 24.63 7.14 Not New one of the Applicable objective subsidiaries, added as per Havix, to fund the the capital shareholder expenditure approval requirements dated Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 for expansion August 03, of the existing 2026 manufacturing facility in Atlanta Total 500.00 418.83 Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised; or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or (c) Change in terms of a contract referred to in the fund-raising documents i.e, prospectus, letter of offer, etc For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary & Compliance Officer Membership Number: A34516 Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263